Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population

Kristin Mondy, Edgar Turner Overton, Jessica Grubb, Shao Tong, Warren Seyfried, William Powderly, Kevin Yarasheski

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

Background. The association between the use of highly active antiretroviral therapy (HAART) and an increased risk of metabolic syndrome and cardiovascular disease remains unclear. Methods. We conducted a prospective, cross-sectional study of the risk factors associated with metabolic syndrome and cardiovascular disease among patients from an urban outpatient human immunodeficiency virus (HIV) clinic. Evaluation included laboratory data that were obtained after an overnight fast and a health survey that assessed traditional risk factors associated with cardiovascular disease, HIV-related factors, and comorbidities. Data collected were compared with data files from a cohort from the National Health and Nutrition Examination Survey (NHANES; 2001-2002) of persons who were seronegative for HIV infection who were matched for age, sex, race, and tobacco use. Results. Four hundred seventy-one HIV-infected subjects provided complete data. The overall prevalence of metabolic syndrome was similar between the group HIV-infected patients and the group of persons who were seronegative for HIV infection (25.5% vs. 26.5%, respectively), although the HIV-infected patients had a significantly smaller waist circumference, lower body mass index, lower high-density lipoprotein cholesterol levels, higher triglyceride levels, and lower glucose levels, compared with the subjects from the NHANES cohort. Framingham 10-year risk scores were also similar between the 2 groups. HIV-infected patients with metabolic syndrome were more likely to be diabetic, older, and white and have a high CD4 cell count and body mass index, compared with patients without metabolic syndrome (P<.05 for all). The type or duration of antiretroviral therapy was not an independent risk factor for metabolic syndrome. Conclusions. The prevalence of metabolic syndrome is high among HIV-infected persons, but not higher than the prevalence among HIV-uninfected persons. Traditional risk factors play a more significant role in the development of metabolic syndrome than do HIV treatment-associated factors.

Original languageEnglish (US)
Pages (from-to)726-734
Number of pages9
JournalClinical Infectious Diseases
Volume44
Issue number5
DOIs
StatePublished - Mar 1 2007

Fingerprint

Outpatients
HIV
Population
Nutrition Surveys
Cardiovascular Diseases
Metabolic Diseases
Virus Diseases
Body Mass Index
Information Storage and Retrieval
Highly Active Antiretroviral Therapy
Tobacco Use
Waist Circumference
CD4 Lymphocyte Count
Health Surveys
HDL Cholesterol
Comorbidity
Triglycerides
Cross-Sectional Studies
Glucose
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Mondy, K., Overton, E. T., Grubb, J., Tong, S., Seyfried, W., Powderly, W., & Yarasheski, K. (2007). Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clinical Infectious Diseases, 44(5), 726-734. https://doi.org/10.1086/511679

Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. / Mondy, Kristin; Overton, Edgar Turner; Grubb, Jessica; Tong, Shao; Seyfried, Warren; Powderly, William; Yarasheski, Kevin.

In: Clinical Infectious Diseases, Vol. 44, No. 5, 01.03.2007, p. 726-734.

Research output: Contribution to journalArticle

Mondy, K, Overton, ET, Grubb, J, Tong, S, Seyfried, W, Powderly, W & Yarasheski, K 2007, 'Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population', Clinical Infectious Diseases, vol. 44, no. 5, pp. 726-734. https://doi.org/10.1086/511679
Mondy, Kristin ; Overton, Edgar Turner ; Grubb, Jessica ; Tong, Shao ; Seyfried, Warren ; Powderly, William ; Yarasheski, Kevin. / Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. In: Clinical Infectious Diseases. 2007 ; Vol. 44, No. 5. pp. 726-734.
@article{5bbbca6aeea64aaf9d624134090eba4d,
title = "Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population",
abstract = "Background. The association between the use of highly active antiretroviral therapy (HAART) and an increased risk of metabolic syndrome and cardiovascular disease remains unclear. Methods. We conducted a prospective, cross-sectional study of the risk factors associated with metabolic syndrome and cardiovascular disease among patients from an urban outpatient human immunodeficiency virus (HIV) clinic. Evaluation included laboratory data that were obtained after an overnight fast and a health survey that assessed traditional risk factors associated with cardiovascular disease, HIV-related factors, and comorbidities. Data collected were compared with data files from a cohort from the National Health and Nutrition Examination Survey (NHANES; 2001-2002) of persons who were seronegative for HIV infection who were matched for age, sex, race, and tobacco use. Results. Four hundred seventy-one HIV-infected subjects provided complete data. The overall prevalence of metabolic syndrome was similar between the group HIV-infected patients and the group of persons who were seronegative for HIV infection (25.5{\%} vs. 26.5{\%}, respectively), although the HIV-infected patients had a significantly smaller waist circumference, lower body mass index, lower high-density lipoprotein cholesterol levels, higher triglyceride levels, and lower glucose levels, compared with the subjects from the NHANES cohort. Framingham 10-year risk scores were also similar between the 2 groups. HIV-infected patients with metabolic syndrome were more likely to be diabetic, older, and white and have a high CD4 cell count and body mass index, compared with patients without metabolic syndrome (P<.05 for all). The type or duration of antiretroviral therapy was not an independent risk factor for metabolic syndrome. Conclusions. The prevalence of metabolic syndrome is high among HIV-infected persons, but not higher than the prevalence among HIV-uninfected persons. Traditional risk factors play a more significant role in the development of metabolic syndrome than do HIV treatment-associated factors.",
author = "Kristin Mondy and Overton, {Edgar Turner} and Jessica Grubb and Shao Tong and Warren Seyfried and William Powderly and Kevin Yarasheski",
year = "2007",
month = "3",
day = "1",
doi = "10.1086/511679",
language = "English (US)",
volume = "44",
pages = "726--734",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population

AU - Mondy, Kristin

AU - Overton, Edgar Turner

AU - Grubb, Jessica

AU - Tong, Shao

AU - Seyfried, Warren

AU - Powderly, William

AU - Yarasheski, Kevin

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Background. The association between the use of highly active antiretroviral therapy (HAART) and an increased risk of metabolic syndrome and cardiovascular disease remains unclear. Methods. We conducted a prospective, cross-sectional study of the risk factors associated with metabolic syndrome and cardiovascular disease among patients from an urban outpatient human immunodeficiency virus (HIV) clinic. Evaluation included laboratory data that were obtained after an overnight fast and a health survey that assessed traditional risk factors associated with cardiovascular disease, HIV-related factors, and comorbidities. Data collected were compared with data files from a cohort from the National Health and Nutrition Examination Survey (NHANES; 2001-2002) of persons who were seronegative for HIV infection who were matched for age, sex, race, and tobacco use. Results. Four hundred seventy-one HIV-infected subjects provided complete data. The overall prevalence of metabolic syndrome was similar between the group HIV-infected patients and the group of persons who were seronegative for HIV infection (25.5% vs. 26.5%, respectively), although the HIV-infected patients had a significantly smaller waist circumference, lower body mass index, lower high-density lipoprotein cholesterol levels, higher triglyceride levels, and lower glucose levels, compared with the subjects from the NHANES cohort. Framingham 10-year risk scores were also similar between the 2 groups. HIV-infected patients with metabolic syndrome were more likely to be diabetic, older, and white and have a high CD4 cell count and body mass index, compared with patients without metabolic syndrome (P<.05 for all). The type or duration of antiretroviral therapy was not an independent risk factor for metabolic syndrome. Conclusions. The prevalence of metabolic syndrome is high among HIV-infected persons, but not higher than the prevalence among HIV-uninfected persons. Traditional risk factors play a more significant role in the development of metabolic syndrome than do HIV treatment-associated factors.

AB - Background. The association between the use of highly active antiretroviral therapy (HAART) and an increased risk of metabolic syndrome and cardiovascular disease remains unclear. Methods. We conducted a prospective, cross-sectional study of the risk factors associated with metabolic syndrome and cardiovascular disease among patients from an urban outpatient human immunodeficiency virus (HIV) clinic. Evaluation included laboratory data that were obtained after an overnight fast and a health survey that assessed traditional risk factors associated with cardiovascular disease, HIV-related factors, and comorbidities. Data collected were compared with data files from a cohort from the National Health and Nutrition Examination Survey (NHANES; 2001-2002) of persons who were seronegative for HIV infection who were matched for age, sex, race, and tobacco use. Results. Four hundred seventy-one HIV-infected subjects provided complete data. The overall prevalence of metabolic syndrome was similar between the group HIV-infected patients and the group of persons who were seronegative for HIV infection (25.5% vs. 26.5%, respectively), although the HIV-infected patients had a significantly smaller waist circumference, lower body mass index, lower high-density lipoprotein cholesterol levels, higher triglyceride levels, and lower glucose levels, compared with the subjects from the NHANES cohort. Framingham 10-year risk scores were also similar between the 2 groups. HIV-infected patients with metabolic syndrome were more likely to be diabetic, older, and white and have a high CD4 cell count and body mass index, compared with patients without metabolic syndrome (P<.05 for all). The type or duration of antiretroviral therapy was not an independent risk factor for metabolic syndrome. Conclusions. The prevalence of metabolic syndrome is high among HIV-infected persons, but not higher than the prevalence among HIV-uninfected persons. Traditional risk factors play a more significant role in the development of metabolic syndrome than do HIV treatment-associated factors.

UR - http://www.scopus.com/inward/record.url?scp=33847073815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847073815&partnerID=8YFLogxK

U2 - 10.1086/511679

DO - 10.1086/511679

M3 - Article

C2 - 17278068

AN - SCOPUS:33847073815

VL - 44

SP - 726

EP - 734

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 5

ER -